Compare · FLNA vs NVO
FLNA vs NVO
Side-by-side comparison of Filana Therapeutics Inc. (FLNA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLNA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 2651.3x FLNA ($69.1M).
- Over the past year, FLNA is down 33.2% and NVO is down 45.7% - FLNA leads by 12.5 points.
- NVO has hit the wire 8 times in the past 4 weeks while FLNA has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for FLNA).
- Company
- Filana Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $1.43+9.16%
- $41.01-4.51%
- Market cap
- $69.1M
- $183.15B
- 1M return
- +5.93%
- -10.44%
- 1Y return
- -33.18%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FLNA
- SEC Form 10-Q filed by Filana Therapeutics Inc.
- Filana Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Filana Therapeutics Reports Q1 2026 Financial Results and Business Update
- Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII
- SEC Form DEF 14A filed by Filana Therapeutics Inc.
- SEC Form 8-K filed by Filana Therapeutics Inc.
- Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
- Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care